Nathan Ihle

Nathan Ihle has extensive experience in the field of oncology research and development. Nathan is currently serving as the Senior Director of Oncology at XinThera, Inc. since May 2021. Prior to this, they worked at Pfizer for eight years, starting as a Research Technician/Specialist in 2013 and steadily progressing to the role of Senior Principal Scientist. At Pfizer, they led project teams in the development of oncology agents and assessed potential targets for development. Before joining Pfizer, Nathan worked at MD Anderson Cancer Center, where they contributed significantly as a Graduate Research Assistant and Program Coordinator. Their work at MD Anderson included research on the KRas oncogene, collaboration with statisticians and clinicians on the BATTLE multi-arm lung cancer trial, and leadership in the development of PX-866, an irreversible pan-PI3K inhibitor. Nathan began their career as a Research Technician/Specialist at The University of Arizona Health Sciences, where they designed and conducted experiments evaluating inhibitors of PI3K and Akt signaling.

Nathan Ihle earned a Bachelor's Degree in Environmental Sciences from the University of Arizona, where they studied from 1996 to 2001. Later, they pursued a Doctor of Philosophy (Ph.D.) in Experimental Therapeutics at The University of Texas Health Science Center at Houston (UTHealth Houston), completing their studies from 2010 to 2012.